Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar Pharmaceuticals, Inc . (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2024. Third quarter Highlights Net revenues of $191.2 million for the third quarter GAAP net income of $40.4 million, or $0.78 per share, for the... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc . (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2024 ended September 30, 2024, after the market closes on Wednesday, November 6, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free 877-407-0989, for... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This... Read More

Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 7, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2024. Second Quarter Highlights Net revenues of $182.4 million for the second quarter GAAP net income of $37.9 million, or $0.73 per share, for the second... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / July 31, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Second quarter of 2024 ended June 30, 2024, after the market closes on Wednesday, August 7, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free 877-407-0989, for international calls,... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that on June 3, 2024, the Company's Board of Directors authorized a $50 million increase to the Company's share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company's equity compensation programs. Purchases may... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 pm EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 22, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that the U.S. Food and Drug Administration ("FDA") has granted approval for the Company's Abbreviated New Drug Application ("ANDA") for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008. This product is for the treatment or prevention of bronchospasm in patients four years of age and older with... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the Bank of America Health Care Conference on Wednesday, May 15th, 2024 at 2:20 pm PDT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will... Read More

Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 8, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2024. First Quarter Highlights Net revenues of $171.8 million for the first quarter GAAP net income of $43.2 million, or $0.81 per share, for the first quarter... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 30, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2024 ended March 31, 2024, after the market closes on Wednesday, May 8, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free 877-407-0989, for international calls,... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 1, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9th, 2024 at 3:00 pm EST. For access, visit Amphastar's... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / March 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Barclays 26 th Annual Global Healthcare Conference on Wednesday, March 13th, 2024 at 11:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will... Read More

Reports Net Revenues of $178.1 Million for the Three Months Ended December 31, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / February 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full-year ended December 31, 2023. Fourth Quarter Highlights Net revenues of $178.1 million for the fourth quarter GAAP net income of $36.2 million, or $0.68 per... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / February 20, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2023 ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free 877-407-0989, for... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 2, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Dr. Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 42 nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:00 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available for 30 days... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 20, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, S.V.P. of Corporate Communications, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 35 th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:30 am EST. For access, visit Amphastar's Pharmaceuticals website at... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 9, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi EVP of Corp. Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 2:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This... Read More

Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / November 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2023. Third Quarter Highlights Net revenues of $180.6 million for the third quarter GAAP net income of $49.2 million, or $0.91 per share, for the... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 1, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2023 ended September 30, 2023, after the market closes on Wednesday, November 8, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free 877-407-0989, for... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / September 13, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar") today announced the pricing of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2029 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / September 11, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar") today announced that it intends to offer, subject to market conditions and other factors, $300.0 million aggregate principal amount of convertible senior notes due 2029 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 31, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Wells Fargo Healthcare Conference on September 7, 2023 at 12:45 pm Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com... Read More

Reports Net Revenues of $145.7 Million for the Three Months Ended June 30, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2023. Second Quarter Highlights Net revenues of $145.7 million for the second quarter GAAP net income of $26.1 million, or $0.49 per share, for the second... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 2, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2023 ended June 30, 2023, after the market closes on Tuesday, August 8, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free 877-407-0989, for international calls,... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / June 30, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today announced that it has completed the previously announced acquisition of BAQSIMI ® from Eli Lilly and Company ("Lilly") (the "Acquisition"). Acquisition Highlights Provides Amphastar with a branded product with growing sales and strong gross margin. Expands Amphastar's international footprint... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 31, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the Jefferies Healthcare Conference on June 8, 2023 at 2:30 pm Eastern Time. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com . This webcast will be available... Read More

Reports Net Revenues of $140.0 Million for the Three Months Ended March 31, 2023 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2023. First Quarter Highlights Net revenues of $140.0 million for the first quarter GAAP net income of $26.0 million, or $0.50 per share, for the first quarter... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 3, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2023 ended March 31, 2023, after the market closes on Tuesday, May 9, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free (888) 645-4404, for international calls, dial... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 24, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will provide a Business update and hold a Conference call today, Monday, April 24, 2023, at 6:00 am Pacific Time. To access the conference call, please dial 877-407-0989, or for international callers, please dial +1 201-389-0921, five minutes before the conference begins. The live call and... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 12, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Jacob Liawatidewi, EVP of Corporate Administration, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 19 th ,... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / March 8, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced that the U.S. Food and Drug Administration ("FDA") has granted approval of its New Drug Application ("NDA") for naloxone hydrochloride nasal spray 4mg, which is delivered utilizing the Company's proprietary nasal delivery device. Naloxone hydrochloride nasal spray 4mg is indicated for the... Read More

Reports Net Revenues of $135.0 Million for the Three Months Ended December 31, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / February 28, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full-year ended December 31, 2022. Fourth Quarter Highlights Net revenues of $135.0 million for the fourth quarter GAAP net income of $33.9 million, or $0.66 per... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / February 22, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2022 ended December 31, 2022, after the market closes on Tuesday, February 28, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free (877) 407-0989, for... Read More

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 30 th , 2022 at 11:00 am Eastern Time. For access, visit Amphastar's Pharmaceuticals... Read More